Amneal Pharmaceuticals price to book ratio AMRX

Market value divided by the book value of the company's net assets, since 2018.

Today, Oct 23, 2026: 197×
8-year median: 4.3×
Against its 8-year history: 100th; percentile: 0 is its lowest day, 100 its highest
8-year range: 1.4× to 197×
Peer median: 10.6×

Amneal Pharmaceuticals' price to book ratio is 197× as of Oct 23, 2026.

That is above its 8-year median of 4.3×, higher than on 100% of days in the last 8 years.

Over that time it ranged from 1.4× in Mar 2023 to 197× in Oct 2026.

The median for 10 large drugmakers of a similar size is 10.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	197×	164×	197×
2025	n/m a value too high to mean anything
2024	105×	5.0×	105×
2023	5.6×	1.4×	5.6×
2022	2.0×	2.0×	4.1×
2021	4.1×	3.5×	7.1×
2020	4.6×	3.6×	7.0×
2019	6.2×	1.6×	8.8×
2018	8.3×	7.8×	14.5×

Against its peers

Companies in Drug Manufacturers - General nearest Amneal Pharmaceuticals' size, closest first, today.

Company	Price to book ratio
AMRXAmneal Pharmaceuticals	197×
LGNDLigand Pharmaceuticals	6.3×
KNSAKiniksa Pharmaceuticals International	9.2×
ALKSAlkermes plc.	4.0×
TGTXTG Therapeutics	13.7×
PTGXProtagonist Therapeutics	10.6×
CORTCorcept Therapeutics	13.2×
INDVIndivior Pharmaceuticals	n/m
ARQTArcutis Biotherapeutics	17.8×
BMRNBiomarin Pharmaceutical	1.7×
LQDALiquidia	19.6×
Peer median	10.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Amneal Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.